Get the Stockscreener App
3.28
0.61%
0.02
Jupiter Neurosciences Inc stock is traded at $3.28, with a volume of 24,747.
It is up +0.61% in the last 24 hours and up +3,066% over the past month.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
See More
Previous Close:
$3.26
Open:
$3.36
24h Volume:
24,747
Relative Volume:
0.00
Market Cap:
$2.53M
Revenue:
$40,400
Net Income/Loss:
$-9.18M
P/E Ratio:
-12.22
EPS:
-0.2684
Net Cash Flow:
$-5.78M
1W Performance:
-21.53%
1M Performance:
+3,066%
6M Performance:
+624.06%
1Y Performance:
+162.40%
1-Day Range:
$3.27
$3.6091
1-Week Range:
$2.88
$3.6499
52-Week Range:
$0.071
$11.20
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences Inc
Sector
Industry
Phone
(561) 406-6154
Address
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
3.28 | 3.98M | 40,400 | -9.18M | -5.78M | -0.2684 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jupiter Neurosciences Inc Stock (JUNS) Latest News
Jupiter Neurosciences, Inc. stock plunges 44% after spiking to $11.14 - Cryptonews.net
Jupiter Neurosciences, Inc. stock Analysis: August 2026 Volatility & Trend Review - The Cryptonomist
Best Pharmaceutical Stocks To Watch TodayAugust 21st - MarketBeat
Friday's session: most active stocks - ChartMill
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Jupiter Neurosciences Prices $2.0 Million Direct Offering - marketscreener.com
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - The Manila Times
Jupiter Neurosciences proposes selling 307,692 shares for about $2 million - Stock Titan
Jupiter Neurosciences Jumps 59% as Volume Hits 59 Times Its Share Count - TechStock²
Jupiter Neurosciences Surges as Post-Split Float Shrinks and Traders Revisit Pipeline Expansion - Quiver Quantitative
JUNS Stock Whipsaws As New Insider Ownership Is Disclosed - timothysykes.com
JUNS Stock Draws Focus After New Insider Ownership Filing - StocksToTrade
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action? - Benzinga
JUNS Stock Jumps As New Insider Ownership Revealed - StocksToTrade
JUNS Stock Jumps As New Insider Ownership Comes To Light - timothysykes.com
Which stocks are moving before the opening bell on Friday? - ChartMill
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
JUNS Stock Whipsaws As New Insider Files Form 3 - StocksToTrade
Jupiter (JUNS) Trading: Posts a 3.81% Loss to $4.80 on the Day; Immediate View: the $4.56 to $5.04 Range Remains in Focus in the Current UpdateEase of Movement - vinanet.vn
Andrew Jon Cutler Net Worth (2026) - GuruFocus
Real Parkinson’s Disease Hope from Jupiter Neurosciences - Yahoo Finance
Jupiter Neurosciences, Inc. Common Stock (NASDAQ: JUNS) Stock Price, News & Analysis - Kalkine
Jupiter (JUNS) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; Post-Report Move: Shares Finish 3.67% Down in the Current UpdateDebt Analysis Report - Vinanet
JUNS Q4 2025 Earnings: Narrower-Than-Expected Loss Meets 6.16% Surprise but Shares Slide 12.67%Dividend Earnings Report - Vinanet
JUNS Q4 2025 Earnings: Narrower Loss Beats Estimates; Shares Slide 12.67%EPS Surprise History - vinanet.vn
JUNS Q4 2025 Earnings: Smaller Loss per Share Beats Estimate, But Shares Slip 12.67%Earnings Call Highlights - Vinanet
Jupiter Neurosciences Inc (JUNS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jupiter Neurosciences Stock Short Interest Falls to 34.91% - Quiver Quantitative
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
JUNS|Jupiter Neurosciences Inc|Price:5.100|Chg%:-0.533 - TradingKey
Market Movers | Winners: ATTO, JUNS, XHLD | Losers: TDUP, BLLN, UWMC - Trefis
Form 8K Jupiter Neurosciences Inc For: 6 August By Investing.com - Investing.com Nigeria
Jupiter Neurosciences Announces 1-for-75 Reverse Stock Split to Regain Nasdaq Compliance - Minichart
Jupiter Neurosciences Enacts 1-for-75 Reverse Stock Split - TipRanks
Jupiter Neurosciences executes 1-for-75 reverse stock split By Investing.com - Investing.com UK
Jupiter Neurosciences grants 472,222 director options | JUNS Insider Trading - Stock Titan
Jupiter Neurosciences executes 1-for-75 reverse stock split - Investing.com
Jupiter Neurosciences, Inc. Announces 1-for-75 Reverse Stock Split Effective August 6, 2026 - Quiver Quantitative
Jupiter Neurosciences, Inc. Announces Reverse Stock Split - GlobeNewswire
Kaskela Law Firm Announces Stockholder Investigation of Jupiter N - The National Law Review
Jupiter Neurosciences expands into psychedelics with $100m deal - Longevity.Technology
JUNS Q4 2025 Earnings: Narrower-Than-Expected Loss Beats Estimates as Pre-Revenue Biotech Maintains Pipeline FocusTax Rate Impact - vinanet.vn
Jupiter Neurosciences (Nasdaq: JUNS) sells 11.47M shares under SEPA - Stock Titan
Jupiter Neurosciences Inc (JUNS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jupiter Neurosciences Stockholders Approve Key 2026 Actions - TipRanks
Jupiter Neurosciences, Inc. Files Form 8-K: Key Details on Nasdaq Listing, Address, and Corporate Status - Minichart
Jupiter Neurosciences (NASDAQ: JUNS) details Yorkville SEPA terms - Stock Titan
Jupiter Neurosciences Inc (JUNS) Cash Flow - TradingKey
Jupiter Neurosciences Inc Stock (JUNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):